Compared with the low-risk group patients, the high-risk NB patients generally showed higher expression of FBP2, NCAN, and AHCY and lower expression of GALNT3 and AKR1C2 in both TS and IVS (Figures S3C and S3D). This evidence concerns the gene AKR1C2 and neuroblastoma.